医学
内科学
中性粒细胞减少症
多发性骨髓瘤
毒性
耐火材料(行星科学)
血液学
胃肠病学
发热性中性粒细胞减少症
外科
物理
天体生物学
作者
Kai Rejeski,Doris K. Hansen,Radhika Bansal,Pierre Sesques,Sikander Ailawadhi,Jennifer M. Logue,Eva Bräunlein,David M. Cordas dos Santos,Ciara L. Freeman,Melissa Alsina,Sebastian Theurich,Yucai Wang,Angela M. Krackhardt,Frederick L. Locke,Emmanuel Bachy,Michael D. Jain,Yi Lin,Marion Subklewe
标识
DOI:10.1186/s13045-023-01465-x
摘要
Abstract Background BCMA-directed CAR T-cell therapy (CAR-T) has altered the treatment landscape of relapsed/refractory (r/r) multiple myeloma, but is hampered by unique side effects that can lengthen hospital stays and increase morbidity. Hematological toxicity (e.g. profound and prolonged cytopenias) represents the most common grade ≥ 3 toxicity and can predispose for severe infectious complications. Here, we examined the utility of the CAR-HEMATOTOX (HT) score to predict toxicity and survival outcomes in patients receiving standard-of-care idecabtagene vicleucel and ciltacabtagene autoleucel. Methods Data were retrospectively collected from 113 r/r multiple myeloma patients treated between April 2021 and July 2022 across six international CAR-T centers. The HT score—composed of factors related to hematopoietic reserve and baseline inflammatory state—was determined prior to lymphodepleting chemotherapy. Results At lymphodepletion, 63 patients were HT low (score 0–1) and 50 patients were HT high (score ≥ 2). Compared to their HT low counterparts, HT high patients displayed prolonged severe neutropenia (median 9 vs. 3 days, p < 0.001), an increased severe infection rate (40% vs. 5%, p < 0.001), and more severe ICANS (grade ≥ 3: 16% vs. 0%, p < 0.001). One-year non-relapse mortality was higher in the HT high group (13% vs. 2%, p = 0.019) and was predominantly attributable to fatal infections. Response rates according to IMWG criteria were higher in HT low patients (≥ VGPR: 70% vs. 44%, p = 0.01). Conversely, HT high patients exhibited inferior progression-free (median 5 vs. 15 months, p < 0.001) and overall survival (median 10.5 months vs. not reached, p < 0.001). Conclusions These data highlight the prognostic utility of the CAR-HEMATOTOX score for both toxicity and treatment response in multiple myeloma patients receiving BCMA-directed CAR-T. The score may guide toxicity management (e.g. anti-infective prophylaxis, early G-CSF, stem cell boost) and help to identify suitable CAR-T candidates.
科研通智能强力驱动
Strongly Powered by AbleSci AI